research use only
Cat.No.S4660
|
In vitro |
Water : 79 mg/mL
DMSO
: 65 mg/mL
(163.18 mM)
Ethanol : 59 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 398.33 | Formula | C19H28NO3.Br |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 596-51-0 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Glycopyrrolate bromide, Glycopyrronium bromide, Robinul, Gastrodyn | SMILES | C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-] | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
Muscarinic receptor
|
|---|---|
| In vitro |
Glycopyrrolate inhibits EFS-induced contraction of guinea-pig trachea and human airways in a concentration-dependent manner. In competition studies, this compound binds human peripheral lung and human airway smooth muscle (HASM) muscarinic receptors with affinities in the nanomolar range (Ki values 0.5–3.6 nM). It showed no selectivity in its binding to the M1–M3 receptors. Kinetics studies show that this chemical dissociates slowly from HASM muscarinic receptors.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2026-04-13)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07282886 | RECRUITING | Asthma |
University of Alabama at Birmingham |
2026-03-15 | PHASE2 |
| NCT05116930 | RECRUITING | Post-Dural Puncture Headache |
Mayo Clinic |
2021-11-19 | PHASE2 |
| NCT07802730 | NOT_YET_RECRUITING | COPD (Chronic Obstructive Pulmonary Disease) |
AeroRx Therapeutics Inc. |
2026-09 | PHASE1 |
| NCT06962007 | RECRUITING | Neuromuscular Blockade Reversal Agent; Perioperative Complications; Anesthesia, General; Sugammadex; Monitoring, Intraoperative; Masseter Muscle Spasm |
Wonkwang University Hospital |
2025-07-01 | |
| NCT07016412 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA |
2025-07-31 | PHASE2 |
| NCT06112353 | COMPLETED | Intestinal Disease |
University of California, Irvine |
2024-04-17 | PHASE4 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.